| payload |
{"created_at":"2026-04-08T19:34:52.231 {"created_at":"2026-04-08T19:34:52.231840+00:00","dedupe_key":"signal_enriched:news_delta:930baf2ddc4377bc","evidence_event_ids":["evt_b1bec9609845"],"signal_type":"news_headline_delta","source":"news_rss","value":{"aggregator_url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc3UxekhjVUVmZWV6SUlwY3BpUjhKZF9lUVBUY2tKTlZjM3piNFZXeDZZZlNtQW15ZGNZOWhFeDJlb2REdW9FNXJ1NzI2OVZGT0FmcFJtMUNaX3NnVk9JXzRjT05EX05ha1c5NmlmdHFXa1kzREV6TlprQzFLSWhqN3JGTnBlU3N2X3pHd1JCeElfMlF6czZxc2dnWHpBclBCajdZcEdPNA?oc=5","as_of":"2026-04-08T19:34:52.231840+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc3UxekhjVUVmZWV6SUlwY3BpUjhKZF9lUVBUY2tKTlZjM3piNFZXeDZZZlNtQW15ZGNZOWhFeDJlb2REdW9FNXJ1NzI2OVZGT0FmcFJtMUNaX3NnVk9JXzRjT05EX05ha1c5NmlmdHFXa1kzREV6TlprQzFLSWhqN3JGTnBlU3N2X3pHd1JCeElfMlF6czZxc2dnWHpBclBCajdZcEdPNA?oc=5","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_1e6c8bbdbe404972","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-09T22:04:17.965731+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc3UxekhjVUVmZWV6SUlwY3BpUjhKZF9lUVBUY2tKTlZjM3piNFZXeDZZZlNtQW15ZGNZOWhFeDJlb2REdW9FNXJ1NzI2OVZGT0FmcFJtMUNaX3NnVk9JXzRjT05EX05ha1c5NmlmdHFXa1kzREV6TlprQzFLSWhqN3JGTnBlU3N2X3pHd1JCeElfMlF6czZxc2dnWHpBclBCajdZcEdPNA?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"theguardian.com","publisher_resolution":"payload_source_domain","requested_url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPc3UxekhjVUVmZWV6SUlwY3BpUjhKZF9lUVBUY2tKTlZjM3piNFZXeDZZZlNtQW15ZGNZOWhFeDJlb2REdW9FNXJ1NzI2OVZGT0FmcFJtMUNaX3NnVk9JXzRjT05EX05ha1c5NmlmdHFXa1kzREV6TlprQzFLSWhqN3JGTnBlU3N2X3pHd1JCeElfMlF6czZxc2dnWHpBclBCajdZcEdPNA?oc=5","source_event_id":"evt_b1bec9609845","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"6a6368bcea306e3a","published_at":"2026-04-08T17:19:00+00:00","publisher_domain":"theguardian.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.55,"dates_mentioned":[],"entities":[{"asset_class":"n/a","name":"Scientists (unnamed)","relevance":"high","symbol":"","type":"group"},{"asset_class":"pharmaceuticals","name":"GLP-1 receptor agonist weight-loss drugs","relevance":"high","symbol":"","type":"drug_class"},{"asset_class":"pharmaceuticals","name":"GLP-1 drugs (general)","relevance":"high","symbol":"","type":"drug_class"},{"asset_class":"media","name":"The Guardian","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"media","name":"Nature.com","relevance":"medium","symbol":"","type":"publisher"},{"asset_class":"media","name":"The Washington Post","relevance":"low","symbol":"","type":"publisher"},{"asset_class":"media","name":"BBC","relevance":"low","symbol":"","type":"publisher"},{"asset_class":"media","name":"Scientific American","relevance":"low","symbol":"","type":"publisher"}],"event_type":"research","information_gaps":["No specific genes/variants, effect sizes, or study design details are included in the provided text.","The exact nature of the \u201cgenetic predictors\u201d (e.g., polygenic scores vs single-gene markers) is not specified.","No timeline is given for clinical translation (e.g., when genetic testing might be used in practice).","No specific GLP-1 drugs (e.g., semaglutide, tirzepatide) are named in the provided excerpt; only the drug class is referenced."],"key_facts":["The Guardian headline states that genetics may help explain why results from weight-loss jabs vary, according to scientists.","The provided source summary indicates genetic predictors of GLP-1 receptor agonist weight loss and side effects were discussed (referenced to Nature.com).","The signal suggests that response to GLP-1 weight-loss drugs may depend on genetics (also echoed by other cited outlets in the source summary)."],"numeric_claims":[],"primary_claim":"Genetics may help explain variability in weight loss outcomes and side effects among people taking GLP-1 (GLP-1 receptor agonist) weight-loss drugs.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Scientists report that genetic factors may help explain why weight-loss results and side effects from GLP-1 receptor agonist drugs vary between individuals. The implication is that genetics could become a factor in predicting who benefits most and who may experience more adverse effects.","topics":["genetics","GLP-1 receptor agonists","weight loss variability","side effects","personalized medicine","biomarkers/predictors"]},"source":"The Guardian","source_domain":"theguardian.com","source_url":"https://www.theguardian.com","summary":"Genetics may help explain why results from weight-loss jabs vary, say scientists The Guardian Genetic predictors of GLP1 receptor agonist weight loss and side effects nature.com If you aren\u2019t losing weight with GLP-1 drugs, this may be one reason why The Washington Post Weight-loss drugs: Who benefits most and why? BBC How well GLP-1 weight loss drugs work may depend on your genetics Scientific American","title":"Genetics may help explain why results from weight-loss jabs vary, say scientists - The Guardian","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}}... |